

innovations


3^{Vol.}12

Novabiochem® NEW • Orthogonal purification strategy for long peptides

- IMAC purification for synthetic peptides
- Higher recoveries than RP-HPLC
- Effective for removal of closely eluting impurities

NEW • IMAC-based chemoselective tag for affinity purification of long peptides

IMAC Tag



In spite of the numerous methodological advances made over the last two decades, the preparation of large peptides and proteins by step-wise solid phase synthesis still remains problematic. This is principally due to difficulties in separating the target molecule from the mixture of closely related truncated and deletion products which arise during the synthetic process. In addition, the purified products, despite giving the appearance of being homogeneous by HPLC analysis, are often heterogeneous, being contaminated with numerous co-eluting sequences which, because they are individually only present in small amounts, escape detection by mass spectrometry.

One solution is to use a method of purification which has a selectivity orthogonal to RP-HPLC. The new chemoselective IMAC tag meets these requirements. It is extremely easy-to-use, gives higher recoveries than RP-HPLC, and is more effective at removing closely eluting impurities. Furthermore, as the purification is an on-off process, it can be readily automated using standard HPLC or FPLC instrumentation.

The mechanism of purification is analogous to HisTag affinity purification, the traditional method in use for isolation and purification of recombinant proteins. The process involves reacting the full length peptide sequence on resin with a cleavable tag which has an affinity for a IMAC column. During peptide synthesis, any failed couplings are capped forming truncated sequences, and so the only amino functionality available to react with the tag is the *N*-terminus of the full length peptide. Following IMAC purification, the tag is removed to give the desired sequence without relying on HPLC alone to obtain the required purity.

The IMAC purification using a copper (II) loaded IDA column is given in method 2. Columns such as HiTrap Chelating HP worked well for this application.

Method 2: Purification of tagged peptide

Buffer preparation

1. Binding buffer for the IMAC chromatography may consist of 20 mM sodium phosphate, 2-8 M urea (depending on peptide solubility) and 0.5 M NaCl. A pH range of 6.5-8.5 can be used.
2. Elution Buffer should have a pH of 3.5. A suggested buffer within this range is citric acid-sodium phosphate system. Elution buffer should also contain Urea (2-8 M) and NaCl (0.5 M).

IMAC purification

1. Charge column with 0.5 column volumes (CV) of 0.1 M CuSO₄ in H₂O.
2. Wash column with 2 CV H₂O, 7.5 CV elution buffer, 10 CV binding buffer.
3. Solubilise crude tagged peptide in binding buffer.
4. Load sample onto IMAC column.
5. Wash any unbound material from the column with 10 CV binding buffer.
6. Elute tagged peptide from column using 20 CV elution buffer.

Method 3: Removal of tag

1. Combine fractions containing purified tagged product. Adjust to pH 11 with 2 M NaOH. If product contains Cys(StBu) add TCEP up to a concentration of 5 mM to remove S-tBu protecting groups simultaneously.
2. Agitate reaction for 1-2 hours at room temperature and then adjust pH to ~4 with 2 M HCl.
3. Separate liberated tag and purified peptide using a second IMAC step or carry out RP-HPLC to combine isolation with desalting.

Example purifications

Application 1: Purification of YLLPRRGPRLGV

The HCV 12mer sequence was tagged and purified using IMAC methodology. The crude peptide was shown to contain a major impurity identified as a capped truncate formed during SPPS (Figure 3). A recovery of 38% pure peptide (99% purity) was obtained after IMAC purification and tag cleavage. For comparison, purification using RP-HPLC gave pure peptide (95%) with a lower recovery of 21%.




Fig. 3: HPLC profiles of YLLPRRGPRLGV before and after IMAC purification.

Application 2: Purification of Gly-GLP (2-36)

Gly-GLP (2-36) was also tagged and purified using IMAC methodology. The crude peptide was shown to contain several impurities identified as capped truncates formed during SPPS (Figure 4). A recovery of 22% pure peptide (89% purity) was obtained after IMAC purification and TAG cleavage. For comparison, purification using RP-HPLC gave pure peptide (81%) with a lower recovery of 5%.




Fig. 4: HPLC profiles of Gly-GLP 2-36 before and after IMAC purification.

Application 3: Purification of Ubiquitin

Ubiquitin was also tagged and purified using IMAC methodology. The crude peptide was shown to contain several impurities identified as capped truncates formed during SPPS (Scheme 4). A recovery of 62% pure peptide (89% purity) was obtained after IMAC purification and TAG cleavage. For comparison, purification using RP-HPLC gave pure peptide (82%) with a lower recovery of 21%.




Fig. 5: HPLC profiles of Ubiquitin before and after IMAC purification.

Ordering Information

Cat.No.	Product	Contents	Price EUR
851208	IMAC tag	250 mg	85.00
NEW	Sold for research use only.	1 g	325.00
Other tags			
851092	4-Nitrophenyl 2-(octadecylsulfonyl)ethyl carbonate	250 mg	52.00
		1 g	180.00

References

1. PCT Application No.: PCT/GB2011/000363

For more information please contact our local offices:

France: 0800 699 620
Germany: 0800 6931 000
Italy: 00800 1166 8811
Spain: 00800 1166 8811
Switzerland: 00800 1166 8811
United Kingdom: 0800 622935

For other countries across Europe, please call:
+44 (0) 115 943 0840

For Technical Service contact:
technical@novabiochem.com



www.merckmillipore.com/novabiochem

Product prices and availability are subject to change. Products are warranted only to meet the specifications set forth on their label/packaging and/or certificate of analysis at the time of shipment or for the expressly stated duration. NO OTHER WARRANTY WHETHER EXPRESS, IMPLIED OR BY OPERATION OF LAW IS GRANTED. The products are intended for research purposes only and are not to be used for drug or diagnostic purposes, or for human use. Merck KGaA's products may not be resold or used to manufacture commercial products without the prior written approval of Merck KGaA. All sales are subject to Merck KGaA's complete Terms and Conditions of Sale (or if sold through an affiliated company of Merck KGaA, such affiliated company's complete Terms and Conditions of Sale). NovaSyn® and Novabiochem® are registered trademarks of Merck KGaA in Australia, Germany, Japan, Switzerland, the United Kingdom, and the United States. SpheriTide® is a registered trademark of SpheriTech in the United Kingdom.
©Copyright 2012 Merck KGaA, Darmstadt, Germany. All rights reserved.